Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms A review of the literature and a long-standing experience of a referral center

被引:73
作者
Brandi, Giovanni [1 ]
Venturia, Michela [1 ]
Pantaleo, Maria Abbondanza [1 ]
Ercolani, Giorgio [2 ]
机构
[1] Univ Bologna, Haematol & Oncol Inst, Dept Expt Diagnost & Specialty Med, St Orsola Malpighi Hosp, 9 Massarenti St, I-40138 Bologna, Italy
[2] Univ Bologna, St Orsola Malpighi Hosp, Dept Med & Surg Sci, Bologna, Italy
关键词
Biliary tract cancer; Diagnosis; Therapy; BILIARY-TRACT CANCER; UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA; PORTAL-VEIN LIGATION; PRETREATMENT PATHOLOGICAL CONFIRMATION; ENDOSCOPIC ENDOPROSTHESIS INSERTION; FUTURE LIVER REMNANT; PHASE-II TRIAL; HILAR CHOLANGIOCARCINOMA; RADIOFREQUENCY ABLATION; EXTRAHEPATIC CHOLANGIOCARCINOMA;
D O I
10.1016/j.dld.2015.11.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In the oncology landscape, cholangiocarcinoma is a challenging disease in terms of both diagnosis and treatment. Besides anamnesis and clinical examination, a definitive diagnosis of cholangiocarcinoma should be supported by imaging techniques (US, CT, MRI) and invasive investigations (ERC or EUS with brushing and FNA or US or CT-guided biopsy) followed by pathological confirmation. Surgery is the main curative option, so resectability of the tumour should be promptly assessed. Moreover, jaundice must be evaluated at the outset because biliary tract decompression with drainage and stent placement may be required. If the patient is resectable, pre-operative assessment of postoperative liver function is mandatory. After a curative resection, an adjuvant therapy may be administered. Otherwise, in cases with macroscopic residual disease after surgery or locally recurrent or unresectable cholangiocarcinoma at the diagnosis, first-line chemotherapy is the preferred strategy, possibly associated with radiotherapy and/or locoregional treatments. As the diagnostic and therapeutic pathway for cholangiocarcinoma can be declined in different modalities, patients should be promptly referred to a multidisciplinary team in a tertiary centre, familiar with this rare but lethal disease. Hence, the aim of the present paper is to focus on diagnostic and therapeutic algorithms based on the common guidelines and also on the clinical practice of multispecialist expert groups. (C) 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:231 / 241
页数:11
相关论文
共 128 条
[1]   THE IMPACT OF RADIATION-DOSE IN COMBINED EXTERNAL-BEAM AND INTRALUMINAL IR-192 BRACHYTHERAPY FOR BILE-DUCT CANCER [J].
ALDEN, ME ;
MOHIUDDIN, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (04) :945-951
[2]  
Anaya Daniel A, 2008, Semin Intervent Radiol, V25, P110, DOI 10.1055/s-2008-1076684
[3]   Adjuvant therapy for resected extrahepatic cholangiocarcinoma: A review of the literature and future directions [J].
Anderson, Carryn ;
Kim, Richard .
CANCER TREATMENT REVIEWS, 2009, 35 (04) :322-327
[4]   A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma [J].
Bamrungphon, Wichuda ;
Prempracha, Nalinee ;
Bunchu, Nophawan ;
Rangdaeng, Samreung ;
Sandhu, Trichak ;
Srisukho, Songphol ;
Boonla, Chanchai ;
Wongkham, Sopit .
CANCER LETTERS, 2007, 247 (02) :301-308
[5]   Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers [J].
Bekaii-Saab, Tanios ;
Phelps, Mitch A. ;
Li, Xiaobai ;
Saji, Motoyasu ;
Goff, Laura ;
Kauh, John Sae Wook ;
O'Neil, Bert H. ;
Balsom, Stephanie ;
Balint, Catherine ;
Liersemann, Ryan ;
Vasko, Vasily V. ;
Bloomston, Mark ;
Marsh, William ;
Doyle, L. Austin ;
Ellison, Gilian ;
Grever, Michael ;
Ringel, Matthew D. ;
Villalona-Calero, Miguel A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2357-2363
[6]   Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial [J].
Bengala, C. ;
Bertolini, F. ;
Malavasi, N. ;
Boni, C. ;
Aitini, E. ;
Dealis, C. ;
Zironi, S. ;
Depenni, R. ;
Fontana, A. ;
Del Giovane, C. ;
Luppi, G. ;
Conte, P. .
BRITISH JOURNAL OF CANCER, 2010, 102 (01) :68-72
[7]   Clinical diagnosis and staging of cholangiocarcinoma [J].
Blechacz, Boris ;
Komuta, Mina ;
Roskams, Tania ;
Gores, Gregory J. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2011, 8 (09) :512-522
[8]   Cholangiocarcinoma [J].
Blechacz, Boris R. A. ;
Gores, Gregory J. .
CLINICS IN LIVER DISEASE, 2008, 12 (01) :131-+
[9]   Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Intrahepatic Cholangiocarcinoma [J].
Boehm, Lucas M. ;
Jayakrishnan, Thejus T. ;
Miura, John T. ;
Zacharias, Anthony J. ;
Johnston, Fabian M. ;
Turaga, Kiran K. ;
Gamblin, T. Clark .
JOURNAL OF SURGICAL ONCOLOGY, 2015, 111 (02) :213-220
[10]   Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma [J].
Borbath, I. ;
Verbrugghe, L. ;
Lai, R. ;
Gigot, J. F. ;
Humblet, Y. ;
Piessevaux, H. ;
Sempoux, C. .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (07) :990-996